Williams Michael D, Joglekar Mugdha V, Hardikar Anandwardhan A, Wong Wilson K M
Diabetes and Islet biology Group, NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Level 6, Medical Foundation Building, 92-94 Parramatta Road, Camperdown, NSW 2050, Australia.
Open Med (Wars). 2020 Jun 19;15(1):567-570. doi: 10.1515/med-2020-0170. eCollection 2020.
Our commentary is focused on three studies that used microRNA overexpression methods for directed differentiation of stem cells into insulin-producing cells. Islet transplantation is the only cell-based therapy used to treat type 1 diabetes mellitus. However, due to the scarcity of cadaveric donors and limited availability of good quality and quantity of islets for transplant, alternate sources of insulin-producing cells are being studied and used by researchers. This commentary provides an overview of distinct studies focused on manipulating microRNA expression to optimize differentiation of embryonic stem cells or induced pluripotent stem cells into insulin-producing cells. These studies have used different approaches to overexpress microRNAs that are highly abundant in human islets (such as miR-375 and miR-7) in their differentiation protocol to achieve better differentiation into functional islet beta (β)-cells.
我们的评论聚焦于三项研究,这些研究采用了微小RNA过表达方法,将干细胞定向分化为胰岛素生成细胞。胰岛移植是用于治疗1型糖尿病的唯一基于细胞的疗法。然而,由于尸体供体稀缺,可供移植的高质量和数量的胰岛有限,研究人员正在研究并使用胰岛素生成细胞的替代来源。本评论概述了不同的研究,这些研究专注于操纵微小RNA表达,以优化胚胎干细胞或诱导多能干细胞向胰岛素生成细胞的分化。这些研究在其分化方案中采用了不同方法来过表达在人胰岛中高度丰富的微小RNA(如miR-375和miR-7),以实现更好地分化为功能性胰岛β细胞。